HIF and reactive oxygen species regulate oxidative phosphorylation in cancer

Eric Hervouet1, Alena Cízková, Jocelyne Demont

  • 1Centre de Génétique Moléculaire et Cellulaire, UMR 5534, Centre National de la Recherche Scientifique, Claude Bernard University of Lyon 1, 43 Boulevard du onze novembre, 69622 Villeurbanne, Cedex, France.

Carcinogenesis
|June 3, 2008
PubMed

Insights

Hypoxia-inducible factor (HIF) regulates oxidative phosphorylation (OXPHOS) in clear cell renal carcinoma (CCRC). HIF stabilization decreases OXPHOS, a process partly mediated by hydroxyl radical production, impacting cancer cell metabolism.

Area of Science:

  • Oncology
  • Cellular Metabolism
  • Biochemistry

Background:

  • Clear cell renal carcinoma (CCRC) is characterized by decreased oxidative phosphorylation (OXPHOS).
  • This metabolic shift is linked to the deficiency of the von Hippel-Lindau (vhl) gene and stabilization of hypoxia-inducible factor (HIF) subunits.
  • Stabilized HIF promotes glycolysis and alters reactive oxygen species (ROS) metabolism.

Purpose of the Study:

  • To investigate the role of HIF in regulating OXPHOS in CCRC.
  • To elucidate the mechanisms by which HIF influences mitochondrial function and ROS production in CCRC cells.

Main Methods:

  • Utilized vhl gene transfection in pVHL-deficient CCRC cells (786-0).
  • Employed RNA interference to inhibit HIF2-alpha synthesis.
  • Stabilized HIF-alpha using CoCl(2) and desferrioxamine (DFO) in CCRC cells with and without pVHL expression.

Main Results:

  • vhl transfection restored respiratory chain subunit content in CCRC cells, despite unchanged transcript levels.
  • HIF2-alpha inhibition also restored respiratory chain subunit content, confirming HIF's regulatory role.
  • HIF stabilization by CoCl(2) decreased respiratory chain subunit levels and increased ROS production, an effect partly mediated by hydroxyl radicals.

Conclusions:

  • HIF plays a critical role in regulating OXPHOS subunit content in CCRC.
  • The HIF-induced decrease in OXPHOS is, in part, mediated by hydroxyl radical production.
  • Targeting HIF and ROS metabolism presents a potential therapeutic strategy for CCRC.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...